Sildeagil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sildeagil

Property Description
Active ingredient Sildenafil (as the citrate salt)
Form Oral tablet, Oral suspension, Injection solution
Pharmacological class Selective Phosphodiesterase-5 (PDE5) Inhibitor
Regulatory Status Prescription Only (Rx)
Origin Synthetic compound

Defining Sildeagil: A Selective PDE5 Inhibitor

Sildeagil is a prescription pharmaceutical preparation whose active ingredient is the chemical compound sildenafil, typically formulated as the citrate salt. This medication is classified as a Phosphodiesterase-5 (PDE5) inhibitor and is recognized as a selective agent for managing conditions related to localized blood flow. The substance is a synthetic compound, having been engineered through medicinal chemistry rather than being derived from a natural source. Sildenafil was the first compound of its class approved for medical use, establishing the entire pharmacological category supported by extensive pharmacological studies.


Composition and Available Drug Forms

The composition of Sildeagil is based on the core component, sildenafil, combined with excipients tailored for administration. While it is predominantly prescribed as an oral film-coated tablet for routine management, the active ingredient is also manufactured as a powder for oral suspension and a sterile solution for injection. The injection form is specifically utilized for intravenous administration in hospital settings when the oral route is not feasible, reflecting the compound's broad application across different routes of delivery.


General Purpose: Enhancing Localized Blood Flow

The general purpose of Sildeagil is to modulate vascular tone within specific tissues. The drug's mechanism involves selective inhibition of the PDE5 enzyme, which prevents the premature breakdown of the chemical messenger cyclic guanosine monophosphate (cGMP). By protecting cGMP, Sildeagil effectively enhances the naturally occurring signal for smooth muscle relaxation and vasodilation. This fundamental action leads to the enhancement of localized blood flow, which is the primary general benefit of the compound. Its status as a Prescription Only (Rx) medicine indicates that its use requires medical supervision.

Regulatory References

  1. Sildenafil - StatPearls (NIH)

What side effects are possible with Sildeagil?

Possible side effects and safety information

The documented safety profile for Sildeagil, whose active ingredient is sildenafil, is established through official regulatory classification systems. The adverse reactions are formally grouped by frequency and the system-organ class affected, consistent with authoritative labeling.

Very Common Adverse Reactions (ge 1 in 10 patients) include headache and flushing. Common Adverse Reactions (ge 1 in 100 to < 1 in 10 patients) involve multiple physiological systems, including dizziness, visual disturbances (such as a color-tinge to vision or blurred vision), nasal congestion, dyspepsia, nausea, back pain, and myalgia.

Documented Serious Safety Considerations

Official labeling identifies several serious adverse reactions reported in temporal association with use. These include Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a cause of decreased vision; sudden decrease or loss of hearing; and Priapism (a prolonged erection lasting longer than four hours).

Serious cardiovascular events such as myocardial infarction and sudden cardiac death have also been reported post-marketing. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Safety Restrictions and Special Populations

The official safety profile mandates several strict constraints. Sildeagil is contraindicated in patients with severe hepatic impairment or a recent history of stroke or myocardial infarction. A critical safety restriction is the absolute contraindication for co-administration with nitrates or nitric oxide donors in any form due to the risk of severe hypotension. Additionally, the use is not recommended for pediatric patients due to reported increased mortality with increasing doses.

Overdose and Emergency Response

The official regulatory documentation for Sildeagil (Sildenafil) establishes that the clinical profile of an overdose is characterized by an increased rate and severity of adverse events typically observed at therapeutic doses. Manifestations associated with exposure higher than the recommended dose may include exaggerated systemic signs such as severe headache and marked flushing, along with a heightened incidence of dyspepsia and abnormal vision.

The official labeling identifies serious systemic vascular effects, specifically hypotension (decreased blood pressure) and syncope (fainting), as potential signs of significantly high drug exposure. A critical, localized outcome documented in regulatory documents is the development of a prolonged erection.

Immediate medical help is required when an erection lasts for a specific duration, typically more than four hours, as explicitly mandated by regulatory authorities.

Management procedures are defined by the lack of a specific counteracting agent; the official labeling states that no specific antidote is known for Sildeagil overdose. Therefore, the mandated clinical action is the institution of symptomatic and supportive treatment, with continuous monitoring necessary for the management of severe cardiovascular manifestations. The official documentation does not detail population-specific overdose manifestations based on age or impairment.

Therapeutic Uses of Sildeagil

Sildeagil is relevant for managing symptoms across therapeutic domains where additional symptomatic support is needed. This medication is commonly used to help with conditions presenting with systemic or localized discomfort.


Supporting Erection and Easing High Lung Pressure

The medication is commonly used to address symptoms related to Erectile Dysfunction (ED) and is also applicable in situations involving Pulmonary Arterial Hypertension (PAH). It helps address symptom clusters that may become intense or disruptive, such as the inability to achieve or maintain an erection, and symptoms linked to organ-specific functional stress, including shortness of breath and reduced ability to exercise. When symptoms interfere with daily functioning, this medicine assists with maintaining functional stability and supports general well-being during symptomatic phases.

“This medicine is considered relevant for easing challenging symptoms across multiple functional domains.”


Quick Fact: Relief for Physiological Strain Sildeagil is commonly used when symptoms create noticeable physiological strain, often during phases when symptoms become more noticeable. The medication helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Sildenafil

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Regulatory documentation defines strict rules regarding who can and cannot use Sildeagil. Use is primarily established for Adults across its approved indications. Safety and efficacy have not been established in children younger than 1 year of age [2.2, 3.1].

Contraindications (Must Not Use)

Classification Population/Condition
Absolute Prohibition Patients using organic nitrates (in any form) or riociguat [1.1, 1.7, 3.3].
Health Status Prohibition Patients with known hypersensitivity to Sildenafil or those for whom sexual activity is inadvisable due to cardiovascular status [1.2, 1.5].
Select Comorbidities Patients with severe hepatic impairment, hypotension (BP <90/50 mmHg), a recent history of stroke or myocardial infarction (within 6 months), or hereditary retinal disorders (e.g., Retinitis Pigmentosa) [1.4, 2.3].

Eligibility-Related Restrictions

Conditional use is required for certain populations. Older adults (ge 65 years) and patients with severe renal or hepatic impairment (Child-Pugh A/B) may require consideration of a restricted starting dosage due to reduced drug clearance [1.5, 2.7]. Sildeagil is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD) [1.3]. For pregnant women, there are no adequate and well-controlled studies [1.6, 2.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information classifies Sildeagil interactions based on two primary mechanisms: additive systemic effects and metabolic clearance alteration.

Co-administration with Organic Nitrates (e.g., Nitroglycerin) and Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is formally contraindicated. This restriction is due to the severe, documented risk of pharmacodynamic reinforcement, which can lead to life-threatening hypotension.

Interactions with the liver’s CYP3A4 enzyme system alter Sildeagil’s plasma concentration. Potent inhibitors like Ritonavir significantly reduce Sildeagil clearance, causing high systemic exposure. For example, when co-administered with Ritonavir, a mandatory dose restriction states that the Sildeagil dose must not exceed 25 mg within 48 hours.

Interaction Type Examples of Interacting Medicines Regulatory Outcome
Metabolic (CYP3A4) Potent CYP3A4 Inhibitors, Inducers Increased/Decreased Plasma Exposure
Pharmacodynamic (Additive) Alpha-Blockers, Antihypertensives Risk of Additive Hypotensive Effects

Co-administration with Alpha-Blockers (e.g., Tamsulosin) carries a regulatory caution regarding the potential for additive blood pressure lowering. Furthermore, a high-fat meal is documented to reduce the rate and extent of Sildeagil absorption. Use with other PDE5 Inhibitors is officially not recommended.

Mechanism of Action

Blocking the PDE5 Enzyme to Amplify Signaling

Sildeagil acts as a selective competitive inhibitor of the enzyme phosphodiesterase type 5 (PDE5), which regulates smooth muscle tone. By binding to and blocking this enzyme, the drug prevents the rapid breakdown of the natural chemical messenger, cGMP (cyclic Guanosine Monophosphate). The resulting accumulation of cGMP contributes to the increase in signal for smooth muscle relaxation in specific blood vessels.


The Cascade Leading to Increased Local Blood Flow

The enhancement of the cGMP signal initiates a mechanistic cascade within the vascular system. Increased cGMP levels lead to the relaxation of the smooth muscle cells that line the blood vessel walls, a process known as vasodilation. This targeted, local widening of blood vessels results in an increase in blood flow to the affected tissue, which is the central physiological consequence of the drug's action.


Dependence on Natural Stimulation

The drug's mechanism is intrinsically linked to the Nitric Oxide (NO) / cGMP pathway and is dependent on a natural physiological signal to become active. Sildeagil only acts to prevent the breakdown of cGMP; it does not initiate its production.

Dosage and Administration Information

How Sildeagil is Used: Official Administration Guidelines

Sildeagil (sildenafil) is administered via two approved routesoral (tablets or suspension) and intravenous (IV) injection—with the official usage protocol highly dependent on the condition being addressed. This differentiation establishes two primary dosing patterns: an 'as needed' regimen for intermittent use and a scheduled, continuous regimen for chronic management.

For intermittent use, such as the Erectile Dysfunction regimen, the typical starting dose is 50 mg oral, which can be adjusted within a range of 25 mg to 100 mg. This form is taken up to once daily, approximately 30 minutes to 4 hours before use. A lower starting dose of 25 mg is considered for patients ge 65 years old, those with severe renal impairment (creatinine clearance < 30 mL/min), or severe hepatic impairment.

For continuous, scheduled use, such as the Pulmonary Arterial Hypertension (PAH) regimen, the standard oral dose is 20 mg taken three times a day (TID), with doses separated by 4 to 6 hours. The IV route, administered as a 10 mg bolus TID, is typically reserved as a temporary measure when a patient cannot tolerate the oral formulation.

Administration Specifics (Official Instructions)
May be taken with or without food; a high-fat meal may delay the onset of activity.
The oral suspension requires reconstitution with water and must be shaken before each dose.
Pediatric dosing (ge 1 year) for PAH is weight-based (mg/kg).

These instructions structure the use of Sildeagil by defining the precise maximum frequency, the temporal relationship to intake, and mandatory dose adjustments based on specific physiological criteria.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sildeagil

Evidence for use in Erectile Dysfunction (ED)

Sildenafil (the active ingredient in Sildeagil) was evaluated in research exploring conditions marked by functional limitations, such as Erectile Dysfunction (ED). This research relied primarily on short-term, placebo-controlled randomized controlled trials (RCTs) used in research exploring how symptoms change over time. The studies primarily examined patient-reported outcomes describing perceived discomfort and overall activity level.

Studies monitored functional ability and monitored physical activity attempts. Findings describe patterns observed in the study populations, where functional variables were monitored during the study period. Research describes the measured changes during the study period, contributing to the broader evidence landscape.

Follow-up durations were limited in the initial controlled studies. As a result, there is limited information for long-term outcomes.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Sildenafil was also evaluated in research involving individuals with conditions related to Pulmonary Arterial Hypertension (PAH). Research primarily utilized short-term, randomized controlled studies that monitored outcomes reflecting daily functioning or activity level, such as the 6-minute walk distance.

Studies report how measured outcomes evolved in the observed populations during the defined time intervals. Research reports measured changes during the study period related to activity level and functional class. Findings indicate patterns of change in activity level measurements in the observed populations, and the evidence contributes to understanding symptom patterns.

However, comparative evidence is limited concerning the use of Sildenafil alongside certain existing therapeutic options. While research provides insight into short-term changes, data on long-term survival effects for the PAH indication remain limited, as follow-up durations were restricted in the primary research.

Evidence Gaps and Research Uncertainty

Data on long-term survival effects for the PAH indication remain limited, as the primary controlled studies were not designed to measure this outcome over many years. Furthermore, subgroup findings are uncertain for certain complex patient characteristics, and the evidence quality varies across studies, particularly concerning the safety profile across different dose levels studied in children. Therefore, study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. FDA Approval of Revatio (Sildenafil) for Pulmonary Arterial Hypertension (Adults)

Frequently Asked Questions (FAQ)

Common questions about Sildeagil (FAQ)


Q: How long after taking Sildeagil can I expect it to start working?

According to official regulatory information, the active ingredient in Sildeagil is typically absorbed rapidly into the bloodstream. Maximum concentrations usually occur about one hour after administration, although this can range from 30 minutes to two hours depending on the individual.


Q: What is the typical duration of effect for Sildeagil?

Studies indicate that the drug's therapeutic effect for conditions like erectile dysfunction can last up to four hours. However, the action is often most pronounced during the first two hours. The drug is gradually cleared from the body, with a terminal half-life typically ranging from three to five hours.


Q: Does eating a large or fatty meal affect how quickly Sildeagil starts to work?

Yes, official product information states that consuming a high-fat meal can affect the rate at which Sildeagil is absorbed by the body. This is documented to reduce both the speed and extent of absorption, potentially delaying the time until the drug starts to work.


Q: Does Sildeagil cause an erection automatically, or is stimulation still required?

The mechanism of action for Sildeagil requires a natural physiological signal to be effective. The medication does not automatically cause an erection; physical or sexual stimulation is still necessary for it to facilitate increased blood flow.


Q: Can Sildeagil be taken if I am already on a medication for high blood pressure?

Regulatory caution is advised when Sildeagil is used with other medications that lower blood pressure, such as alpha-blockers or other antihypertensives, due to the potential for additive hypotensive effects. This interaction is noted in official product information.


Q: What happens if I forget when I last took Sildeagil and take it again too soon?

Official dosing guidelines define a maximum frequency for its use (e.g., up to once per day for intermittent use). Studies involving high single doses in healthy volunteers found that adverse events were similar to those seen at lower doses, but occurred at increased rates and severities.


Q: Is Sildeagil a blood pressure medication, or just for blood flow to a specific area?

Sildeagil is indicated to treat two distinct conditions: those related to localized blood flow, such as erectile dysfunction, and a form of high blood pressure known as pulmonary arterial hypertension (PAH), which specifically affects the arteries in the lungs.


Q: Does Sildeagil treat the underlying cause of a condition, or just the symptoms?

Studies indicate that the drug's mechanism of action enhances a natural chemical process within the body (vasodilation) to relieve symptoms. This action is designed to improve functional ability, for example, by increasing exercise capacity in patients with PAH.


Q: Is it possible to have an overdose on Sildeagil, and what are the signs?

Official labeling addresses the possibility of overdose. Studies involving healthy volunteers who received very high doses found that the adverse events they experienced were similar to those seen at standard doses, but occurred more frequently and were more severe.


Q: Are there any different brand names for Sildeagil that treat different conditions?

Yes, the active ingredient, sildenafil, is marketed under different brand names depending on the medical condition it is intended to treat. For example, one brand is typically used for pulmonary arterial hypertension (PAH), and a separate brand is generally used for erectile dysfunction (ED).


Q: What Sildeagil is used for besides the main condition people talk about?

Beyond its primary, approved uses for erectile dysfunction and pulmonary arterial hypertension, official drug information indicates that the active ingredient has also been studied. It is sometimes discussed in relation to symptoms of secondary Raynaud's phenomenon, although this is not an an approved indication.


Q: Can women take Sildeagil for any medical condition?

Yes, the active ingredient in Sildeagil is approved for use in adult women. It is specifically indicated for the treatment of pulmonary arterial hypertension (PAH), a condition involving high blood pressure in the arteries of the lungs.


Q: Does Sildeagil have a generic version available?

Yes, the Food and Drug Administration (FDA) has approved generic versions of the active ingredient, sildenafil. These generics are available for both the erectile dysfunction and the pulmonary arterial hypertension indications.


Q: Can Sildeagil interact with common over-the-counter pain relievers like ibuprofen?

Interactions between the active ingredient and common over-the-counter pain relievers like ibuprofen are not typically reported in standard drug interaction resources. It is recommended to inform a healthcare provider of all medicines being taken, as comprehensive interaction data is not always available.


Q: Can people with diabetes safely use Sildeagil?

Clinical trials for the ED indication have included men with diabetes. It is crucial to remember that the drug is strictly contraindicated for use with nitrates, which are frequently prescribed for heart conditions that may be associated with diabetes.


Q: What's the difference between Sildeagil and Tadalafil/Vardenafil?

Sildeagil, Tadalafil, and Vardenafil belong to the same pharmacological group known as PDE5 inhibitors, and they share a similar mechanism of action. The main differences between these compounds lie in their chemical structure, the time they take to start working, and their overall duration of effect in the body.


Q: Can Sildeagil cause dizziness, and what should I do if that happens?

Dizziness is listed as a common adverse reaction in official safety documents. Regulatory guidance suggests that if dizziness occurs, resting or sitting until the feeling subsides may be necessary. It is advised that individuals refrain from driving or operating machinery if they feel dizzy.


Q: Are there any specific vitamins or supplements that interact dangerously with Sildeagil?

Supplements are not subject to the same rigorous testing as prescription medicines, so a complete safety profile cannot be provided. Official guidance strongly recommends informing a healthcare provider about all supplements, vitamins, and herbal remedies being taken.


Q: What are the signs of an allergic reaction to Sildeagil?

Signs of a serious allergic reaction may include a rash that is swollen, itchy, blistered, or peeling, as well as swelling of the face, tongue, or lips. If signs of a serious allergic reaction occur, immediate medical attention is necessary.


Q: Can Sildeagil be used by people with kidney or liver problems?

The use of Sildeagil in patients with existing kidney or liver conditions requires specific consideration. Official regulatory documents indicate that severe hepatic impairment requires specific eligibility rules, and patients with severe renal or less severe hepatic impairment may require consideration of a reduced starting dosage.


Q: Can Sildeagil make symptoms of heartburn or indigestion worse?

Indigestion and dyspepsia are common adverse reactions documented for Sildeagil. Some reports indicate that taking the medication with a meal may help reduce this type of digestive discomfort.


Q: What is the general success rate reported in clinical trials for Sildeagil?

Clinical trials reported varying success rates depending on the group studied and the underlying cause of the condition being treated. For the erectile dysfunction indication, reported rates of functional improvement ranged significantly, for example, from lower rates for men with diabetes to higher rates for men with psychogenic (non-physical) causes.


Q: Why is Sildeagil sometimes prescribed for conditions in the lungs (pulmonary hypertension)?

Sildeagil is prescribed for pulmonary hypertension because the PDE5 enzyme, which it blocks, is highly concentrated in the blood vessels of the lungs. By inhibiting this enzyme, the drug causes the blood vessels in the lungs to widen and relax, effectively helping to lower the high blood pressure in the pulmonary arteries.


Q: Is a stuffy nose a recognized side effect of Sildeagil?

Yes, a stuffy nose, referred to in official documents as nasal congestion, is recognized as a common adverse reaction. This side effect is a result of the drug's general mechanism of widening blood vessels throughout the body.


Q: What are the safety concerns for people with sickle cell anemia who take Sildeagil?

Official precautions highlight that patients with a condition like sickle cell anemia must use the drug with caution. This is because they may have an increased risk of developing Priapism, which is a prolonged erection that can cause permanent tissue damage.

How should Sildeagil be stored and disposed of?

How to Store and Dispose of Sildeagil?

Regulatory labeling dictates specific storage and disposal requirements for Sildeagil, which vary by formulation.

Sildeagil oral tablets and the powder for suspension must be stored at controlled room temperature, 20 C to 25 C, with permitted temperature excursions up to 30 C. The unopened injection solution must be stored in the original carton to protect from light.

Once the oral suspension powder is mixed, it has a stability limit of 60 days and must not be frozen. All forms of the medicine must be stored out of the sight and reach of children.

Disposal of unused or expired product must be carried out according to local requirements and should not be thrown away via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sildeagil found in:

A-Z Index: